I thank D. Monneret and J-P. Bastard for their interest in our manuscript [1] and I could not agree more with their comment that the role of soluble CD163 (sCD163) in obstructive sleep apnoea (OSA) requires further detailed evaluation. As outlined in our article, the measurement of sCD163 in our patient cohort followed our results from the in vitro and in vivo studies demonstrating M1 polarisation of adipose tissue macrophages in response to intermittent hypoxia and thus, was not an a priori hypothesis of our study. Nonetheless, the detected independent association of sCD163 with OSA severity is intriguing. sCD163 in sleep apnoea requires further evaluation http://ow.ly/o3R130d82YZ

中文翻译：

---

血清 sCD163 作为阻塞性睡眠呼吸暂停患者脂肪组织炎症的生物标志物：局限性和前景

我感谢 D. Monneret 和 JP。混蛋，因为他们对我们的手稿 [1] 感兴趣，我完全同意他们的评论，即可溶性 CD163 (sCD163) 在阻塞性睡眠呼吸暂停 (OSA) 中的作用需要进一步详细评估。正如我们的文章中所述，我们的患者队列中 sCD163 的测量遵循了我们的体外和体内研究结果，表明脂肪组织巨噬细胞对间歇性缺氧做出反应的 M1 极化，因此，这不是我们研究的先验假设。尽管如此，检测到的 sCD163 与 OSA 严重程度的独立关联很有趣。睡眠呼吸暂停中的 sCD163 需要进一步评估 http://ow.ly/o3R130d82YZ